ArticleScientific reports2016
Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with Cationic Polymers for Cancer Immunotherapy.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- Article
- Multifactorial effects of LGALS1 blockade sensitize tumors to immune checkpoint inhibitor.Experimental hematology & oncology · 2026Article
- An injectable hydrogel enhances intratumoral retention and antitumor efficacy of cytokine immunotherapy in murine triple negative breast tumor models.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Immunoregulatory iPSC-derived non-lymphoid progeny in autoimmunity and GVHD alloimmunity.Stem cells (Dayton, Ohio) · 2025Review
- Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy.Journal of hematology & oncology · 2025Review
- Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer.International journal of molecular sciences · 2024Review
- Drug delivery methods for cancer immunotherapy.Drug delivery and translational research · 2024Review
- Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer.Advanced drug delivery reviews · 2023Review
- ICAM-1-decorated extracellular vesicles loaded with miR-146a andBiomaterials science · 2023Article
- Evaluation of the Cytotoxicity of Cationic Polymers on Glioblastoma Cancer Stem Cells.Journal of functional biomaterials · 2022Article
- Intracellular mRNA phase separation induced by cationic polymers for tumor immunotherapy.Journal of nanobiotechnology · 2022Article
- Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy.Bioactive materials · 2022Article
- In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloid-Derived Suppressor Cells.Advanced healthcare materials · 2022Article
- RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics.Molecular cancer · 2022Review
- Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine.International journal of nanomedicine · 2022Article
- Review
- Advances in technology and applications of nanoimmunotherapy for cancer.Biomarker research · 2021Review
- Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines.Pharmaceutics · 2021Review
- Review
- Using nanoparticles forInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our evolving understandings of cell-material interactions provide insights for using polymers to modulate cell behaviour that may lead to therapeutic applications. It is known that in certain cancers, myeloid-derived suppressor cells (MDSCs) play vital roles in promoting tumour progression, chiefly because of their 'alternatively activated' (or M2) phenotype that orchestrates immunosuppression. In this study, we demonstrated that two cationic polymers - cationic dextran (C-dextran) and polyethyleneimine (PEI) - could directly remodel these cells into an anti-tumour, 'classically activated' (or M1) phenotype, thereby stimulating these cells to express tumouricidal cytokines, reactivating the T cell functions, and prolonging the lifespan of the mice model. Our investigations with knock-out mice further indicate that the functions of these cationic polymers require the involvement of toll-like receptor 4-mediated signalling. Taken together, our study suggests that these cationic polymers can effectively and directly re-polarize MDSCs from an immunosuppressive characteristic to an anti-tumour phenotype, leading to successful restoration of immune surveillance in the tumour microenvironment and elimination of tumour cells. Our findings may have immediate impact on further development of polymer-based therapeutics for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.